Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-10-28 4:16 pm Purchase | 2026-10-21 | 13G | CONTINEUM THERAPEUTICS INC CL CTNM | Squadron Master Fund LP | 1,700,000 5.100% | 1,700,000 (New Position) | Filing History |
| 2026-10-23 4:15 pm Purchase | 2026-10-16 | 13G | TCX CALIBUR INC - TCXB | Squadron Master Fund LP | 650,000 5.000% | 650,000 (New Position) | Filing History |
| 2026-08-14 1:24 pm Sale | 2026-06-30 | 13G | TRAWS PHARMA, INC PAR TRAW | Squadron Master Fund LP | 0 0.000% | -511,714 (Position Closed) | Filing History |
| 2026-08-14 1:17 pm Sale | 2026-06-30 | 13G | RELMADA THERAPEUTICS INC P RLMD | Squadron Master Fund LP | 7,350,000 7.000% | -45,510 (-0.62%) | Filing History |
| 2026-08-14 1:09 pm Sale | 2026-06-30 | 13G | NEXTCURE INC NXTC | Squadron Master Fund LP | 64,464 1.600% | -206,663 (-76.22%) | Filing History |
| 2026-08-14 1:01 pm Purchase | 2026-06-30 | 13G | LIPOCINE INC INC LPCN | Squadron Master Fund LP | 810,000 9.800% | 360,000 (+80.00%) | Filing History |
| 2026-08-14 12:54 pm Purchase | 2026-06-30 | 13G | C4 THERAPEUTICS INC CCCC | Squadron Master Fund LP | 7,600,000 6.900% | 2,050,000 (+36.94%) | Filing History |
| 2026-08-04 3:06 pm Purchase | 2026-07-28 | 13G | IRULYA THERAPEUTICS INC IRLA | Squadron Master Fund LP | 55,173 5.600% | 55,173 (New Position) | Filing History |
| 2026-05-27 4:08 pm Purchase | 2026-05-19 | 13G | INMED PHARMACEUTICALS INC INM | Squadron Master Fund LP | 325,000 9.800% | 325,000 (New Position) | Filing History |
| 2026-05-19 4:09 pm Purchase | 2026-05-12 | 13G | C4 THERAPEUTICS INC CCCC | Squadron Master Fund LP | 5,550,000 5.000% | 5,550,000 (New Position) | Filing History |
| 2026-05-15 12:02 pm Sale | 2026-03-31 | 13G | SPRUCE BIOSCIENCES INC SPRB | Squadron Master Fund LP | 12,200 0.900% | -57,800 (-82.57%) | Filing History |
| 2026-05-15 11:55 am Sale | 2026-03-31 | 13G | LIPOCINE INC INC LPCN | Squadron Master Fund LP | 450,000 6.200% | -80,000 (-15.09%) | Filing History |
| 2026-05-15 11:50 am Sale | 2026-03-31 | 13G | TRAWS PHARMA, INC PAR TRAW | Squadron Master Fund LP | 511,714 6.400% | -201,826 (-28.29%) | Filing History |
| 2026-04-08 12:46 pm Purchase | 2026-03-31 | 13G | SCYNEXIS INC SCYX | Squadron Master Fund LP | 951,087 9.600% | 951,087 (New Position) | Filing History |
| 2026-04-07 4:26 pm Purchase | 2026-03-30 | 13G | APREA THERAPEUTICS INC APRE | Squadron Master Fund LP | 1,271,081 9.900% | 1,271,081 (New Position) | Filing History |
| 2026-03-03 4:05 pm Purchase | 2026-02-24 | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Squadron Master Fund LP | 3,676,900 5.100% | 3,676,900 (New Position) | Filing History |
| 2026-02-17 12:36 pm Purchase | 2025-12-31 | 13G | TRAWS PHARMA, INC PAR TRAW | Squadron Master Fund LP | 713,540 8.900% | 122,540 (+20.73%) | Filing History |
| 2026-02-17 12:27 pm Unchanged | 2025-12-31 | 13G | SPRUCE BIOSCIENCES INC SPRB | Squadron Master Fund LP | 70,000 6.500% | 0 (Unchanged) | Filing History |
| 2026-02-17 12:18 pm Purchase | 2025-12-31 | 13G | RELMADA THERAPEUTICS INC P RLMD | Squadron Master Fund LP | 7,395,510 9.900% | 4,097,010 (+124.21%) | Filing History |
| 2026-02-17 12:09 pm Sale | 2025-12-31 | 13G | PALISADE BIO INC COM P PALI | Squadron Master Fund LP | 4,500,000 3.000% | -3,750,000 (-45.45%) | Filing History |